Posted by Michael Wonder on 13 Aug 2020
Predictors of negotiated prices for new drugs in Germany
13 August 2020 - In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration.
The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of new, non-orphan innovative medicines in Germany.
